Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% and liver triglycerides by 67% compared to placebo two months after administration Data also.
Fractyl Health Presents Compelling Preclinical Data from globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
BURLINGTON, Mass., May 07, 2024 Fractyl Health, Inc. , a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes , today announced.